» Authors » Michael D Roth

Michael D Roth

Explore the profile of Michael D Roth including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 94
Citations 3515
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Volkmann E, Tashkin D, Leng M, Kim G, Goldin J, Harui A, et al.
ERJ Open Res . 2025 Feb; 11(1). PMID: 39902269
Background And Objectives: The extent and pattern of radiological features ( fibrosis and ground glass) can influence treatment approaches for systemic sclerosis-related interstitial lung disease (SSc-ILD). However, the pathobiology underlying...
2.
Li L, Chen H, Zhu Y, Harui A, Roth M
Sci Rep . 2024 Dec; 14(1):31683. PMID: 39738260
Electronic cigarettes (e-cigs) fundamentally differ from tobacco cigarettes in their generation of liquid-based aerosols. Investigating how e-cig aerosols behave when inhaled into the dynamic environment of the lung is important...
3.
Volkmann E, Wilhalme H, Tashkin D, Kim G, Goldin J, Haussmann A, et al.
Arthritis Care Res (Hoboken) . 2024 Dec; PMID: 39711034
Objective: This study investigated whether changes in circulating biomarkers predict progressive pulmonary fibrosis (PPF) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) receiving treatment. Methods: Participants of the Scleroderma...
4.
Chen H, Harui A, Feng Y, Li L, Patel S, Schmidt J, et al.
Environ Sci Technol . 2024 Dec; 58(52):22919-22929. PMID: 39681299
Traditional in vitro and in vivo models for inhalation toxicology studies often fail to replicate the anatomical and physiological conditions of the human lung. This limitation hinders our understanding of...
5.
Volkmann E, Tashkin D, Silver R, Bostwick C, Assassi S, Baker Frost D, et al.
Lancet Rheumatol . 2023 Sep; 4(10):e668-e678. PMID: 37745675
Background: Observational studies have shown that men with systemic sclerosis have an increased risk of interstitial lung disease (ILD) and mortality compared with women. However, previous studies have not controlled...
6.
Volkmann E, Wilhalme H, Assassi S, Kim G, Goldin J, Kuwana M, et al.
ACR Open Rheumatol . 2023 Aug; 5(10):547-555. PMID: 37592449
Objective: Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to...
7.
Volkmann E, Tashkin D, Leng M, Kim G, Goldin J, Roth M
Arthritis Care Res (Hoboken) . 2022 Dec; 75(8):1690-1697. PMID: 36504432
Objective: To investigate whether symptoms of gastroesophageal reflux disease and radiographic measures of esophageal dilation are associated with radiographic progression of systemic sclerosis-related interstitial lung disease (SSc-ILD). Methods: Participants of...
8.
Harui A, Roth M
Gels . 2022 May; 8(5). PMID: 35621582
Immunotherapy targeting checkpoint inhibitors, such as CTLA-4 and/or PD-1, has emerged as a leading cancer therapy. While their combination produces superior efficacy compared to monotherapy, it also magnifies inflammatory and...
9.
Wareing N, Mohan V, Taherian R, Volkmann E, Lyons M, Wilhalme H, et al.
Arthritis Care Res (Hoboken) . 2022 Mar; 75(3):648-656. PMID: 35287250
Objective: To assess the predictive significance of blood neutrophil count and the ratio between neutrophil and lymphocyte count (neutrophil-to-lymphocyte ratio [NLR]) for disease severity and mortality in systemic sclerosis (SSc)....
10.
Assassi S, Volkmann E, Zheng W, Wang X, Wilhalme H, Lyons M, et al.
Ann Rheum Dis . 2022 Feb; 81(6):854-860. PMID: 35190386
Objectives: To characterise the peripheral blood cell (PBC) gene expression changes ensuing from mycophenolate mofetil (MMF) or cyclophosphamide (CYC) treatment and to determine the predictive significance of baseline PBC transcript...